Cargando…
Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity
Cancer vaccines offer the potential to enhance T cell-mediated antitumor immunity by expanding and increasing the function of tumor-specific T cells and shaping the recall response against recurring tumors. While the use of cancer vaccines is not a new immunotherapeutic approach, the cancer vaccine...
Autores principales: | Hernandez, Rosmely, Malek, Thomas R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150178/ https://www.ncbi.nlm.nih.gov/pubmed/35651800 http://dx.doi.org/10.3389/fonc.2022.878377 |
Ejemplares similares
-
High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4(+) and CD8(+) neoantigen-specific T cells to promote antitumor immunity
por: Hernandez, Rosmely, et al.
Publicado: (2021) -
Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8(+) T cells
por: LaPorte, Kathryn M, et al.
Publicado: (2023) -
Improvement of Antitumor Therapies Based on Vaccines and Immune-Checkpoint Inhibitors by Counteracting Tumor-Immunostimulation
por: Chiarella, Paula, et al.
Publicado: (2018) -
Endogenous Retroviruses as Targets for Antitumor Immunity in Renal Cell Cancer and Other Tumors
por: Cherkasova, Elena, et al.
Publicado: (2013) -
P. aeruginosa Mediated Necroptosis in Mouse Tumor Cells Induces Long-Lasting Systemic Antitumor Immunity
por: Qi, Jia-long, et al.
Publicado: (2021)